- Home
- RDFN vs COLL Comparison
RDFN vs COLL Comparison
Compare RDFN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- COLL
- Stock Information
- Founded
- RDFN 2002
- COLL 2002
- Country
- RDFN United States
- COLL United States
- Employees
- RDFN N/A
- COLL N/A
- Industry
- RDFN Real Estate
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- COLL Health Care
- Exchange
- RDFN Nasdaq
- COLL Nasdaq
- Market Cap
- RDFN 1.1B
- COLL 1.0B
- IPO Year
- RDFN 2017
- COLL 2015
- Fundamental
- Price
- RDFN $7.90
- COLL $32.59
- Analyst Decision
- RDFN Hold
- COLL Strong Buy
- Analyst Count
- RDFN 11
- COLL 5
- Target Price
- RDFN $9.43
- COLL $43.80
- AVG Volume (30 Days)
- RDFN 4.1M
- COLL 426.9K
- Earning Date
- RDFN 02-25-2025
- COLL 02-20-2025
- Dividend Yield
- RDFN N/A
- COLL N/A
- EPS Growth
- RDFN N/A
- COLL 757.11
- EPS
- RDFN N/A
- COLL 2.16
- Revenue
- RDFN $1,016,774,000.00
- COLL $599,245,000.00
- Revenue This Year
- RDFN $8.63
- COLL $13.25
- Revenue Next Year
- RDFN $9.90
- COLL $18.14
- P/E Ratio
- RDFN N/A
- COLL $15.07
- Revenue Growth
- RDFN 3.70
- COLL 9.62
- 52 Week Low
- RDFN $5.10
- COLL $28.39
- 52 Week High
- RDFN $15.29
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- RDFN 45.98
- COLL 56.03
- Support Level
- RDFN $7.60
- COLL $31.19
- Resistance Level
- RDFN $8.18
- COLL $33.99
- Average True Range (ATR)
- RDFN 0.42
- COLL 1.42
- MACD
- RDFN 0.10
- COLL 0.14
- Stochastic Oscillator
- RDFN 66.67
- COLL 74.01
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.